📌 Key Takeaways
- Topic: Pharmaceutical Grade Silica: Specifications, USP/EP Standards and Uses as an Excipient
- Keywords: Denka spherical silica
- Published: 2026-11-20 10:22:56
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is TEOS? Uses in Sol-Gel Silica, Coatings and Semiconductors
- What Is Hydrophobic Fumed Silica? Surface Treatment, Grades and Applications
- Silica for Electronic Encapsulation: Purity, CTE and Particle Size Requirements
- 600 Mesh Silica: Particle Size, Specifications and Common Applications
- Data Availability Statement
- What Is Nano Silica? Particle Size, Properties, Production and Applications
- Mathematical modeling, particularly the application of the Fick diffusion equation, is really beneficial in clarifying and predicting drug release from polymeric or porous matrices. Fick's laws describe diffusion as the movement of molecules from a greatly concentrated region to a region where the concentration is lower. Fick's first law presumes the diffusion flux to be directly proportional to the concentration gradient. Fick's second law controls the spatial and temporal change in concentration in the release medium [ 59 ]. For drug release, the general equation is as follows (Equation (3)).
What Is the Boiling Point of Silica (SiO₂)? Thermal Properties Explained
What is silica (SiO₂)?
thixotropic agent for epoxy
What is the difference between fumed silica and precipitated silica?
precipitated silica market
What drives silica raw material prices?
is silica soluble in water MSNs are SiO 2 nanoparticles [ 2 ] with a pore diameter between 2 and 50 nm [ 3, 4 ] and with a total diameter of a maximum of 1 µm. Their use in drug delivery dates to the early 1990s when they were synthesized for various scientific applications [ 5 ]. The material known as mesoporous silica was discovered by Mobil Oil Corporation in 1992 [ 6 ]. Their first drug delivery application was demonstrated in 2001 when MCM-41 silica was used to release ibuprofen [ 7 ]. Since then, MSNs have become an increasingly popular drug delivery system due to their advantageous properties and have been typically recognized as secure (GRAS) by the FDA. Tiny SNPs have been approved for human clinical imaging studies, setting the stage for their use in clinical applications of drug delivery. The number of related research activities is continuously increasing each year, expanding their role in cancer treatment, gene delivery, and oral illness therapy [ 5 ]. Their pore size is located between microporous and macroporous systems. They can be used in diverse shapes (sphere, cube, ellipsoid, rod) and sizes, with different pore sizes and pore structures [ 2, 3, 4, 8, 9, 10 ]. They have a high degree of stability [ 8 ] and a rigid framework, which results in resistance to temperature, pH, enzymatic degradation, and mechanical force [ 4 ]. Thanks to the large number of pores, they have a massive particular surface region (approx. 700-1300 m 2 /g) and pore volume (approx. 0.5-1.5 cm 3 /g), which enables effective adsorption of diverse molecules [ 2, 3, 4, 8, 9, 10 ]. By changing the pore size distribution, the range of adsorbable molecules can be controlled [ 3 ], which also lets separation based on size exclusion, which means selective adsorption of molecules of certain sizes. Depending on the size of the pores, tiny molecules together with high molecular weight proteins can be transported into the pores [ 8 ]. In addition, chemical separation is also possible if the surface of the pores is coated with specific functional groups [ 4 ], which enables the separation of the APIs according to their structure [ 4 ]. Such modifications may include the setting of hydrophilicity/hydrophobicity of the surface, depending on whether the adsorption of hydrophobic or hydrophilic molecules is targeted [ 4 ]. By inserting different functional groups, the surface charge can also be controlled so that certain molecules will bind more efficiently. MSNs have a negative surface charge in biological environments, which promotes the electrostatic adsorption of positively charged APIs in the pores [ 10 ]. Moreover, the biological markers attached to the surface of the nanoparticles enable the drug-carrying system to deliver the API in a tissue-specific manner [ 2, 4, 8, 9, 10 ]. A substantial problem is the premature release of the API from the pores during transport [ 4, 8 ], which can be solved by utilizing gatekeepers that respond to special stimuli and keep the pores closed until the stimulus [ 2, 4, 8 ]. In this way, controlled drug delivery and stimuli-responsive release can be achieved [ 2, 4, 9 ]. The drug release could be triggered by temperature, pH, redox potential, light, enzymes, magnetic field, or different ligands [ 4, 8, 11 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.